← SEC 公告列表 | IRMD SEC 公告 | iRadimed公司（IRMD）

重大事件 即時報告 8-K 2026-06-24

Iradimed股東會通過董事選舉、核數師委任及高管薪酬案

於 SEC 網站開啟原文

AI 繁中摘要

Iradimed Corporation（納斯達克代號：IRMD）於2026年6月24日提交8-K表格，報告2026年6月23日舉行的年度股東大會投票結果。三項提案均獲通過，具體如下： 1. **董事選舉**：五位候選人全部當選，任期至下次年度股東大會或繼任者獲選為止，其中 Roger Susi（8,638,178 票贊成，1,972,758 票反對，759,594 票券商未投票）、Monty Allen（9,266,549 票贊成，1,344,387 票反對）、Joe Kiani（10,492,206 票贊成，118,730 票反對）、Hilda Scharen-Guivel（10,409,481 票贊成，201,455 票反對）及 James Hawkins（8,244,802 票贊成，2,366,134 票反對）。 2. **批准核數師**：股東以壓倒性票數（11,355,891 票贊成，8,716 票反對，5,923 票棄權）確認委任 RSM US LLP 為截至2026年12月31日止財政年度的獨立註冊會計師事務所。 3. **高管薪酬諮詢決議**：約98.9% 的投票股東（10,487,387 票贊成，106,030 票反對，17,519 票棄權，另有759,594 券商未投票）通過了對公司指定高管的薪酬方案的顧問性決議。 所有提案均獲所需多數支持，「券商未投票」在董事選舉及高管薪酬投票中未被計入，但對核數師批准決議無影響。這意味著股東對現有董事會組成、審計安排及薪酬政策表示信心，短期內公司治理架構維持不變。投資者應留意董事會成員變動（如 James Hawkins 獲較多反對票）及未來可能跟進的薪酬披露事宜。
展開英文正文 
irmd-202606240001325618FALSE00013256182026-06-242026-06-24

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
Date of report (Date of earliest event reported): June 24, 2026
IRADIMED CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)

001-3653473-1408526
(Commission File Number)(IRS Employer Identification No.)

12705 Ingenuity Drive, Orlando, Florida
32826
(Address of principal executive offices)(Zip Code)

(407) 677-8022
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Securities registered pursuant to Section 12(b) of the Act:

Title of each class:Trading SymbolName of each exchange on which registered:
Common stock, par value $0.0001IRMDNASDAQ Global Market

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Annual Meeting of Stockholders of Iradimed Corporation (“Iradimed”) was held on Tuesday, June 23, 2026. At the meeting, Iradimed’s stockholders voted on the following three proposals and cast their votes as described below.

1.Stockholders elected each of Roger Susi, Monty Allen, Joe Kiani, Hilda Scharen-Guivel and James Hawkins to Iradimed’s Board of Directors, each to hold office until a succeeding annual meeting of stockholders or until such director’s successor shall have been duly elected and qualified (or, if earlier, such director’s removal or resignation from our Board), as set forth below.

NameVotes ForVotes WithheldBroker Non-Votes
Roger Susi8,638,1781,972,758759,594
Monty Allen9,266,5491,344,387759,594
Joe Kiani10,492,206118,730759,594
Hilda Scharen-Guivel10,409,481201,455759,594
James Hawkins8,244,8022,366,134759,594

2.Stockholders ratified the selection of RSM US LLP as Iradimed’s independent registered public accounting firm to perform independent audit services for the fiscal year ending December 31, 2026, as set forth below.

Votes ForVotes AgainstAbstentions
11,355,8918,7165,923

3.Stockholders approved an advisory resolution on the compensation of Iradimed’s named executive officers.

Votes ForVotes AgainstAbstentionsBroker Non-Votes
10,487,387106,03017,519759,594

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IRADIMED CORPORATION 

Date: June 24, 2026

By: /s/John Glenn 
Name: John Glenn
Title: Chief Financial Officer